×
Hero Background

Osteomyelitis Companies

ID: MRFR/Pharma/4584-HCR
90 Pages
Rahul Gotadki
October 2025

Osteomyelitis is a bacterial infection of the bone, often requiring a combination of medical and surgical interventions for effective treatment. Companies involved in addressing osteomyelitis play a crucial role in the development, manufacturing, and distribution of products and technologies related to the diagnosis and treatment of this condition. 

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Osteomyelitis Market Research Report – Forecast to 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Osteomyelitis Market

Osteomyelitis Key Companies

 

Latest Osteomyelitis Companies Update


September 2023: A Phase II trial begins evaluating the efficacy of phage therapy for treating chronic osteomyelitis, exploring a potential alternative to traditional antibiotics.August 2023: Researchers at the University of Pennsylvania develop a new imaging technique for early detection of osteomyelitis, potentially improving diagnosis and treatment outcomes.July 2023: A study published in Nature Reviews Rheumatology highlights the importance of personalized medicine approaches in managing osteomyelitis based on individual patient factors and microbial pathogens.July 2023: Osteotech Inc. receives FDA clearance for its OsteoGraf-DBM PLUS bone growth stimulator with integrated demineralized bone matrix, aiming to enhance bone healing in osteomyelitis patients.June 2023: K2M receives FDA approval for its Mobi-C cervical artificial disc, potentially offering a long-term solution for treating spinal osteomyelitis and preventing complications.April 2023: Merck launches Zeptera™ (ceftobiprole medoxomil), a new antibiotic specifically indicated for diabetic foot infections, a common form of osteomyelitis.

 

List of Osteomyelitis Key Companies in the Market



  • Allergan Plc (Republic of Ireland)

  • CrystalGenomics Inc (South Korea)

  • Debiopharm International SA (Lausanne)

  • Motif Bio Plc (London)

  • Nabriva Therapeutics AG (Dublin)

  • Vyome Biosciences Pvt Ltd (India)

  • F. Hoffmann-La Roche AG (Switzerland)

  • Koninklijke Philips N.V. (Netherlands)

  • General Healthcare (U.S.)

  • Siemens AG (Germany)

  • Toshiba Corporation (Japan)

  • Shimadzu Corporation (Japan)

  • Samsung Electronics Co., Ltd. (South Korea)

  • Neusoft Medical Systems Co., Ltd. (China)

  • Medtronic plc (Ireland)

  • Shenzhen Anke High-tech Co., Ltd. (Hong Kong)